Cargando…

Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy

SIMPLE SUMMARY: Intra-and inter-tumor heterogeneity characterizes breast cancer disease not only in terms of intrinsic cancer cell features, but also of its surrounding microenvironment that can be characterized by different stromal and immune cell types. Nonetheless, triple-negative breast cancers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perrone, Milena, Talarico, Giovanna, Chiodoni, Claudia, Sangaletti, Sabina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699132/ https://www.ncbi.nlm.nih.gov/pubmed/34944971 http://dx.doi.org/10.3390/cancers13246352

Ejemplares similares

Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
por: Lecis, Daniele, et al.
Publicado: (2019)

ATF3 Reprograms the Bone Marrow Niche in Response to Early Breast Cancer Transformation
por: Perrone, Milena, et al.
Publicado: (2023)

The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response
por: Cascini, Caterina, et al.
Publicado: (2021)

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities
por: Sangaletti, Sabina, et al.
Publicado: (2019)

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2(+) breast cancer
por: Janiszewska, Michalina, et al.
Publicado: (2021)

Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation
por: Tripodo, Claudio, et al.
Publicado: (2022)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Myeloid cell heterogeneity in lung cancer: implication for immunotherapy
por: Sangaletti, Sabina, et al.
Publicado: (2021)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces
por: Sangaletti, Sabina, et al.
Publicado: (2020)

Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy
por: Ma, Youzhao, et al.
Publicado: (2023)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
por: Shin, Junyoung, et al.
Publicado: (2023)

Triggering CD40 on endothelial cells contributes to tumor growth
por: Chiodoni, Claudia, et al.
Publicado: (2006)

Potential Biomarkers Associated with Prognosis and Trastuzumab Response in HER2+ Breast Cancer
por: Castro-Guijarro, Ana Carla, et al.
Publicado: (2023)

Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling
por: Rizzello, Celeste, et al.
Publicado: (2022)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
por: Hou, Yanjun, et al.
Publicado: (2023)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
por: Chen, Hai-long, et al.
Publicado: (2023)

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017)

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
por: Fasching, Peter A., et al.
Publicado: (2023)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions
por: Bassani, Barbara, et al.
Publicado: (2021)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer
por: Feng, Wanjing, et al.
Publicado: (2020)

Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines
por: Vargas-Rondón, Natalia, et al.
Publicado: (2020)

Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy
por: Di Martino, Maria Teresa, et al.
Publicado: (2018)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer
por: Teruya, Natsuki, et al.
Publicado: (2023)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer
por: Chiodoni, C., et al.
Publicado: (2023)

Histologic heterogeneity predicts patient prognosis of HER2‐positive metastatic breast cancer: A retrospective study based on SEER database
por: Wang, Yajie, et al.
Publicado: (2023)

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)

Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies
por: Sangaletti, Sabina, et al.
Publicado: (2014)

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
por: Cosgrove, Nicola, et al.
Publicado: (2023)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

The antitumor immune response in HER-2 positive, metastatic breast cancer patients
por: Juranic, Zorica D, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_skqqb212itmr2fcosfbv4dkdpu